Instructions
Online Submissions
Join Us
Signup For Alerts
Home
About JC
Editorial Board
Articles
Browse Articles
Search Articles
Special Issues
Most Popular
Most cited
Contacts
Contact Us
Subscribe Online
Feedback
Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Most popular articles (Since August 15, 2008)
Archives
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Viewed
PDF
Cited
SHORT PAPER
BRAF
V600E
mutations in malignant melanoma are associated with increased expressions of BAALC
David Schrama, Gunhild Keller, Roland Houben, Christian G Ziegler, Claudia S Vetter-Kauczok, Selma Ugurel, Jurgen C Becker
2008, 7:1 (16 July 2008)
DOI
:10.1186/1477-3163-7-1
PMID
:18631381
Bachground:
Activating
BRAF
mutations are present in approximately 50% of melanomas. Although different downstream target genes of the most common mutant V600E have been identified, the contribution of activating
BRAF
mutations to malignant transformation needs further clarification.
Methods:
Microarray gene analysis was performed for human melanoma cell lines harboring BRAF
V600E
mutations in comparison to cell lines without this mutation.
Results:
This analysis revealed a more than two fold down-regulation of 43 and an increase of 39 gene products.
BAALC
(
Brain and acute Leukaemia, cytoplasmatic
) was most prominently regulated, since it was up-regulated in mutated cell lines by a mean of 11.45. Real time PCR analyses with RNA from melanoma cell lines (n = 30) confirmed the
BRAF
-activation dependent up-regulation of
BAALC
.
Conclusion:
BAALC
, which has been associated with cell dedifferentiation and migration, may function as a downstream effector of activating
BRAF
mutations during melanomagenesis.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
7,678
784
1
RESEARCH
Colorectal carcinogenesis: Review of human and experimental animal studies
Takuji Tanaka
2009, 8:5 (26 March 2009)
DOI
:10.4103/1477-3163.49014
PMID
:19332896
This review gives a comprehensive overview of cancer development and links it to the current understanding of tumorigenesis and malignant progression in colorectal cancer. The focus is on human and murine colorectal carcinogenesis and the histogenesis of this malignant disorder. A summary of a model of colitis-associated colon tumorigenesis (an AOM/DSS model) will also be presented. The earliest phases of colorectal oncogenesis occur in the normal mucosa, with a disorder of cell replication. The large majority of colorectal malignancies develop from an adenomatous polyp (adenoma). These can be defined as well-demarcated masses of epithelial dysplasia, with uncontrolled crypt cell proliferation. When neoplastic cells pass through the muscularis mucosa and infiltrate the submucosa, they are malignant. Carcinomas usually originate from pre-existing adenomas, but this does not imply that all polyps undergo malignant changes and does not exclude
de novo
oncogenesis. Besides adenomas, there are other types of pre-neoplasia, which include hyperplastic polyps, serrated adenomas, flat adenomas and dysplasia that occurs in the inflamed colon in associated with inflammatory bowel disease. Colorectal neoplasms cover a wide range of pre-malignant and malignant lesions, many of which can easily be removed during endoscopy if they are small. Colorectal neoplasms and/or pre-neoplasms can be prevented by interfering with the various steps of oncogenesis, which begins with uncontrolled epithelial cell replication, continues with the formation of adenomas and eventually evolves into malignancy. The knowledge described herein will help to reduce and prevent this malignancy, which is one of the most frequent neoplasms in some Western and developed countries.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
6,413
1,939
38
Reactive oxygen species: Role in the development of cancer and various chronic conditions
Gulam Waris, Haseeb Ahsan
2006, 5:14 (11 May 2006)
DOI
:10.1186/1477-3163-5-14
PMID
:16689993
Oxygen derived species such as superoxide radical, hydrogen peroxide, singlet oxygen and hydroxyl radical are well known to be cytotoxic and have been implicated in the etiology of a wide array of human diseases, including cancer. Various carcinogens may also partly exert their effect by generating reactive oxygen species (ROS) during their metabolism. Oxidative damage to cellular DNA can lead to mutations and may, therefore, play an important role in the initiation and progression of multistage carcinogenesis. The changes in DNA such as base modification, rearrangement of DNA sequence, miscoding of DNA lesion, gene duplication and the activation of oncogenes may be involved in the initiation of various cancers. Elevated levels of ROS and down regulation of ROS scavengers and antioxidant enzymes are associated with various human diseases including various cancers. ROS are also implicated in diabtes and neurodegenerative diseases. ROS influences central cellular processes such as proliferation a, apoptosis, senescence which are implicated in the development of cancer. Understanding the role of ROS as key mediators in signaling cascades may provide various opportunities for pharmacological intervention.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
6,092
1,337
105
ORIGINAL ARTICLE
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
Neelu Puri, Ravi Salgia
2008, 7:9 (5 December 2008)
DOI
:10.4103/1477-3163.44372
PMID
:19240370
Background:
c-Met and EGFR receptors are widely expressed on cancer cells; they are implicated in the development and progression of cancer through a plethora of effects on cell cycle progression, apoptosis, motility and metastasis and are potential targets for combination therapy. EGFR receptor tyrosine kinases are currently being targeted in a number of malignancies.
Methods:
Apoptosis was studied by FACS analysis using propidium iodide. EGF and HGF signaling intermediates were studied by western blotting. Cell proliferation was determined by MTT assays. Cell motility was done by time lapse confocal microscopy.
Results:
c-Met and EGFR were both expressed in A549, H1838, H2170, SW900, SW1573, H358, SKLU-1, and H1993 non small cell lung cancer (NSCLC) cell lines. Both EGF and HGF at 100 ng/ml in medium showed a synergistic effect on cell proliferation at 48-72 h as seen by a proliferation assay in A549, H1838, and SKMES cells. In A549 and H1838 cell lines, HGF (40 ng/ml) and EGF (5 ng/ml) induced synergistic phosphorylation on c-Met (Tyr 1003/1230/1234/1235). Additionally, synergistic phosphorylation of Akt (Ser-473) and phospho-ERK1+ERK2 (Thr202/Tyr204) was also seen indicating that EGF and HGF could induce synergistic phosphorylation of important signaling intermediates. Treatment with EGF and HGF at 100 ng/ml for 2 h also leads to an additive effect in inducing cell motility (especially membrane ruffling) in H1993 cells. A novel c-Met small molecule tyrosine kinase inhibitor SU11274 and EGFR tyrosine kinase inhibitors Tyrphostin AG1478 and gefitinib (Iressa) were tested to study their effect in combination on proliferation and apoptosis in lung cancer cells. Interestingly, a synergistic effect on inhibition of cell proliferation was seen in the presence of SU11274 and Tyrphostin AG1478. 0.5 µM Tyrphostin AG1478 and 2 µM SU11274 inhibited growth by 21% and 25%, respectively; a combination of both tyrosine kinase inhibitors inhibited growth by 65%. Interestingly, EGFR inhibitor (gefitinib, Iressa) and c-Met inhibitor (SU11274) also had a synergistic effect on apoptosis in H358 cells.
Conclusion:
There was a synergistic effect of EGF and HGF on proliferation, downstream activation of signal transduction and an additive effect seen on motility. These studies show that a combination of HGF and EGF tyrosine kinase inhibitors on NSCLC, could potentially be targeted in a synergistic fashion.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
4,487
1,336
26
p53 regulates mtDNA copy number and mitocheckpoint pathway
Mariola Kulawiec, Vanniarajan Ayyasamy, Keshav K Singh
2009, 8:8 (6 May 2009)
DOI
:10.4103/1477-3163.50893
PMID
:19439913
Background:
We previously hypothesized a role for mitochondria damage checkpoint (mito-checkpoint) in maintaining the mitochondrial integrity of cells. Consistent with this hypothesis, defects in mitochondria have been demonstrated to cause genetic and epigenetic changes in the nuclear DNA, resistance to cell-death and tumorigenesis. In this paper, we describe that defects in mitochondria arising from the inhibition of mitochondrial oxidative phosphorylation (mtOXPHOS) induce cell cycle arrest, a response similar to the DNA damage checkpoint response.
Materials and Methods:
Primary mouse embryonic fibroblasts obtained from p53 wild-type and p53-deficient mouse embryos (p53 -/-) were treated with inhibitors of electron transport chain and cell cycle analysis, ROS production, mitochondrial content analysis and immunoblotting was performed. The expression of p53R2 was also measured by real time quantitative PCR.
Results:
We determined that, while p53 +/+ cells arrest in the cell cycle, p53 -/- cells continued to divide after exposure to mitochondrial inhibitors, showing that p53 plays an important role in the S-phase delay in the cell cycle. p53 is translocated to mitochondria after mtOXPHOS inhibition. Our study also revealed that p53-dependent induction of reactive oxygen species acts as a major signal triggering a mito-checkpoint response. Furthermore our study revealed that loss of p53 results in down regulation of p53R2 that contributes to depletion of mtDNA in primary MEF cells.
Conclusions:
Our study suggests that p53 1) functions as mito-checkpoint protein and 2) regulates mtDNA copy number and mitochondrial biogenesis. We describe a conceptual organization of the mito-checkpoint pathway in which identified roles of p53 in mitochondria are incorporated.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
4,548
1,230
28
Protein expression analysis of inflammation-related colon carcinogenesis
Yumiko Yasui, Takuji Tanaka
2009, 8:10 (2 June 2009)
DOI
:10.4103/1477-3163.51851
PMID
:19491504
Background:
Chronic inflammation is a risk factor for colorectal cancer (CRC) development. The aim of this study was to determine the differences in protein expression between CRC and the surrounding nontumorous colonic tissues in the mice that received azoxymethane (AOM) and dextran sodium sulfate (DSS) using a proteomic analysis.
Materials and Methods:
Male ICR mice were given a single intraperitoneal injection of AOM (10 mg/kg body weight), followed by 2% (w/v) DSS in their drinking water for seven days, starting one week after the AOM injection. Colonic adenocarcinoma developed after 20 weeks and a proteomics analysis based on two-dimensional gel electrophoresis and ultraflex TOF/TOF mass spectrometry was conducted in the cancerous and nontumorous tissue specimens.
Results:
The proteomic analysis revealed 21 differentially expressed proteins in the cancerous tissues in comparison to the nontumorous tissues. There were five markedly increased proteins (beta-tropomyosin, tropomyosin 1 alpha isoform b, S100 calcium binding protein A9, and an unknown protein) and 16 markedly decreased proteins (Car1 proteins, selenium-binding protein 1, HMG-CoA synthase, thioredoxin 1, 1 Cys peroxiredoxin protein 2, Fcgbp protein, Cytochrome c oxidase, subunit Va, ETHE1 protein, and 7 unknown proteins).
Conclusions:
There were 21 differentially expressed proteins in the cancerous tissues of the mice that received AOM and DSS. Their functions include metabolism, the antioxidant system, oxidative stress, mucin production, and inflammation. These findings may provide new insights into the mechanisms of inflammation-related colon carcinogenesis and the establishment of novel therapies and preventative strategies to treat carcinogenesis in the inflamed colon.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
4,466
1,160
14
SPECIAL ISSUE ON CANCER PREVENTION AND DETECTION
Androgen receptor signaling in prostate cancer development and progression
Peter E Lonergan, Donald J Tindall
2011, 10:20 (23 August 2011)
DOI
:10.4103/1477-3163.83937
PMID
:21886458
The androgen receptor (AR) signaling axis plays a critical role in the development, function and homeostasis of the prostate. The classical action of AR is to regulate gene transcriptional processes via AR nuclear translocation, binding to androgen response elements on target genes and recruitment of, or crosstalk with, transcription factors. Prostate cancer initiation and progression is also uniquely dependent on AR. Androgen deprivation therapy remains the standard of care for treatment of advanced prostate cancer. Despite an initial favorable response, almost all patients invariably progress to a more aggressive, castrate-resistant phenotype. Considerable evidence now supports the concept that development of castrate-resistant prostate cancer (CRPC) is causally related to continued transactivation of AR. Understanding the critical events and complexities of AR signaling in the progression to CRPC is essential in developing successful future therapies. This review provides a synopsis of AR structure and signaling in prostate cancer progression, with a special focus on recent findings on the role of AR in CRPC. Clinical implications of these findings and potential directions for future research are also outlined.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
5,122
460
-
SHORT COMMUNICATION
Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach
Brian J Wilson
2008, 7:6 (1 October 2008)
DOI
:10.4103/1477-3163.43426
PMID
:19008565
The GATA3 transcription factor is expressed in many tissues such as the immune system, kidney, brain, endometrium, and mammary epithelial cells. As such it must co-ordinate a diverse transcriptional program to achieve specific outcomes in different tissues. One of the most interesting questions raised is whether GATA3 will be involved in the same pathways in every tissue or will be involved in distinct regulatory networks within different tissue types? While previous studies may imply the latter, with some known targets of GATA3 perhaps being specific to cell-type or tissue-type, the question has not been systematically addressed until now. With the advent of techniques such as co-expression meta-analysis a better understanding of the pathway partners of GATA3 can be obtained and specifically the partners within different tissue types can be found, yielding leads for future studies. Here, a recent technique of meta-analysis from the Oncomine database has been employed to probe this very question. Data obtained implies that GATA3 is involved in distinct pathways in different tissue types.
[ABSTRACT]
[FULL TEXT]
[PDF]
[PubMed]
4,651
699
-
SPECIAL ISSUE - COLORECTAL CARCINOGENESIS AND PREVENTION
The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies
Mariangela De Robertis, Emanuela Massi, Maria Luana Poeta, Simone Carotti, Sergio Morini, Loredana Cecchetelli, Emanuela Signori, Vito Michele Fazio
2011, 10:9 (24 March 2011)
DOI
:10.4103/1477-3163.78279
PMID
:21483655
Colorectal cancer (CRC) is a major health problem in industrialized countries. Although inflammation-linked carcinogenesis is a well accepted concept and is often observed within the gastrointestinal tract, the underlying mechanisms remain to be elucidated. Inflammation can indeed provide initiating and promoting stimuli and mediators, generating a tumour-prone microenvironment. Many murine models of sporadic and inflammation-related colon carcinogenesis have been developed in the last decade, including chemically induced CRC models, genetically engineered mouse models, and xenoplants. Among the chemically induced CRC models, the combination of a single hit of azoxymethane (AOM) with 1 week exposure to the inflammatory agent dextran sodium sulphate (DSS) in rodents has proven to dramatically shorten the latency time for induction of CRC and to rapidly recapitulate the aberrant crypt foci-adenoma-carcinoma sequence that occurs in human CRC. Because of its high reproducibility and potency, as well as the simple and affordable mode of application, the AOM/DSS has become an outstanding model for studying colon carcinogenesis and a powerful platform for chemopreventive intervention studies. In this article we highlight the histopathological and molecular features and describe the principal genetic and epigenetic alterations and inflammatory pathways involved in carcinogenesis in AOM/DSS-treated mice; we also present a general overview of recent experimental applications and preclinical testing of novel therapeutics in the AOM/DSS model.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
5,103
195
-
RESEARCH
Does architectural lighting contribute to breast cancer?
Mariana G Figueiro, Mark S Rea, John D Bullough
2006, 5:20 (10 August 2006)
DOI
:10.1186/1477-3163-5-20
PMID
:16901343
Objectives:
There is a growing interest in the role that light plays on nocturnal melatonin production and, perhaps thereby, the incidence of breast cancer in modern societies. The direct causal relationships in this logical chain have not, however, been fully established and the weakest link is an inability to quantitatively specify architectural lighting as a stimulus for the circadian system. The purpose of the present paper is to draw attention to this weakness.
Data Sources and Extraction:
We reviewed the literature on the relationship between melatonin, light at night, and cancer risk in humans and tumor growth in animals. More specifically, we focused on the impact of light on nocturnal melatonin suppression in humans and on the applicability of these data to women in real-life situations. Photometric measurement data from the lighted environment of women at work and at home is also reported.
Data Synthesis:
The literature review and measurement data demonstrate that more quantitative knowledge is needed about circadian light exposures actually experienced by women and girls in modern societies.
Conclusion:
Without such quantitative knowledge, limited insights can be gained about the causal relationship between melatonin and the etiology of breast cancer from epidemiological studies and from parametric studies using animal models.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
4,157
888
14
SPECIAL ISSUE - COLORECTAL CARCINOGENESIS AND PREVENTION
Wnt signaling and colon carcinogenesis: Beyond APC
Rani Najdi, Randall F Holcombe, Marian L Waterman
2011, 10:5 (17 March 2011)
DOI
:10.4103/1477-3163.78111
PMID
:21483657
Activation of the Wnt signaling pathway via mutation of the
adenomatous polyposis coli
gene (APC) is a critical event in the development of colon cancer. For colon carcinogenesis, however, constitutive signaling through the canonical Wnt pathway is not a singular event. Here we review how canonical Wnt signaling is modulated by intracellular LEF/TCF composition and location, the action of different Wnt ligands, and the secretion of Wnt inhibitory molecules. We also review the contributions of non-canonical Wnt signaling and other distinct pathways in the tumor micro environment that cross-talk to the canonical Wnt pathway and thereby influence colon cancer progression. These 'non-APC' aspects of Wnt signaling are considered in relation to the development of potential agents for the treatment of patients with colon cancer. Regulatory pathways that influence Wnt signaling highlight how it might be possible to design therapies that target a network of signals beyond that of APC and β-catenin.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
4,889
110
-
ORIGINAL ARTICLE
d
-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis
Thangaiyan Rabi, Anupam Bishayee
2009, 8:9 (21 May 2009)
DOI
:10.4103/1477-3163.51368
PMID
:19465777
Background:
Clinical trials have shown that docetaxel combined with other novel agents can improve the survival of androgen-independent prostate cancer patients.
d
-Limonene, a non-nutrient dietary component, has been found to inhibit various cancer cell growths without toxicity. We sought to characterize whether a non-toxic dose of
d
-limonene may enhance tumor response to docetaxel in an
in vitro
model of metastatic prostate cancer.
Materials and Methods:
Human prostate carcinoma DU-145 and normal prostate epithelial PZ-HPV-7 cells were treated with various concentrations of
d
-limonene, docetaxel or a combination of both, and cell viability was determined by MTT assay. Intracellular reactive oxygen species (ROS), reduced glutathione (GSH) and caspase activity were measured. Apoptosis and apoptosis-related proteins were studied by enzyme-linked immunosorbent assay and Western blotting, respectively.
Results:
d
-Limonene and docetaxel in combination significantly enhanced the cytotoxicity to DU-145 cells than PZ-HPV-7 cells. Exposure of DU-145 cells to a combined
d
-limonene and docetaxel resulted in higher ROS generation, depletion of GSH, accompanied by increased caspase activity than docetaxel alone. It also triggered a series of effects involving cytochrome
c
, cleavages of caspase-9, 3 and poly (ADP-ribose) polymerase, and a shift in Bad:Bcl-xL ratio in favor of apoptosis. Apoptotic effect was significantly blocked on pretreatment with
N
-acetylcystein, indicating that antitumor effect is initiated by ROS generation, and caspase cascades contribute to the cell death.
Conclusion:
Our results show, for the first time, that
d
-limonene enhanced the antitumor effect of docetaxel against prostate cancer cells without being toxic to normal prostate epithelial cells. The combined beneficial effect could be through the modulation of proteins involved in mitochondrial pathway of apoptosis.
d
-Limonene could be used as a potent non-toxic agent to improve the treatment outcome of hormone-refractory prostate cancer with docetaxel.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
4,053
819
11
REVIEW ARTICLE
Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications
Athanassios Kyrgidis, Thrasivoulos-George Tzellos, Stefanos Triaridis
2010, 9:3 (1 April 2010)
DOI
:10.4103/1477-3163.62141
PMID
:20442802
Background
:The classification and prognostic assessment of melanoma is currently based on morphologic and histopathologic biomarkers. Availability of an increasing number of molecular biomarkers provides the potential for redefining diagnostic and prognostic categories and utilizing pharmacogenomics for the treatment of patients. The aim of the present review is to provide a basis that will allow the construction-or reconstruction-of future melanoma research.
Methods:
We critically review the common medical databases (PubMed, EMBASE, Scopus and Cochrane CENTRAL) for studies reporting on molecular biomarkers for melanoma. Results are discussed along the hallmarks proposed for malignant transformation by Hanahan and Weinberg. We further discuss the genetic basis of melanoma with regard to the possible stem cell origin of melanoma cells and the role of sunlight in melanoma carcinogenesis.
Results:
Melanocyte precursors undergo several genome changes -UV-induced or not- which could be either mutations or epigenetic. These changes provide stem cells with abilities to self-invoke growth signals, to suppress anti-growth signals, to avoid apoptosis, to replicate without limit, to invade, proliferate and sustain angiogenesis. Melanocyte stem cells are able to progressively collect these changes in their genome. These new potential functions, drive melanocyte precursors to the epidermis were they proliferate and might cause benign nevi. In the epidermis, they are still capable of acquiring new traits via changes to their genome. With time, such changes could add up to transform a melanocyte precursor to a malignant melanoma stem cell.
Conclusions
: Melanoma cannot be considered a "black box" for researchers anymore. Current trends in the diagnosis and prognosis of melanoma are to individualize treatment based on molecular biomarkers. Pharmacogenomics constitute a promising field with regard to melanoma patients' treatment. Finally, development of novel monoclonal antibodies is expected to complement melanoma patient care while a number of investigational vaccines could find their way into everyday oncology practice.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
3,841
939
5
RESEARCH
MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis
Reema Mallick, Santosh Kumar Patnaik, Sai Yendamuri
2010, 9:8 (3 August 2010)
DOI
:10.4103/1477-3163.67074
PMID
:20808843
MicroRNAs are tiny non-coding RNA molecules which play important roles in the epigenetic control of cellular processes by preventing the translation of proteins from messenger RNAs (mRNAs). A single microRNA can target different mRNAs, and an mRNA can be targeted by multiple microRNAs. Such complex interplays underlie many molecular pathways in cells, and specific roles for many microRNAs in physiological as well as pathological phenomena have been identified. Changes in expression of microRNAs have been associated with a wide variety of disease conditions, and microRNA-based biomarkers are being developed for the identification and monitoring of such states. This review provides a general overview of the current state of knowledge about the biology of microRNAs, and specific information about microRNAs with regard to the diagnosis and prognosis of lung cancer.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
3,244
1,031
3
REVIEW
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors
Shoshana J Weiner, Siyamek Neragi-Miandoab
2008, 7:3 (28 July 2008)
DOI
:10.1186/1477-3163-7-3
PMID
:18662397
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor for which no effective therapy exists despite the discovery of many possible molecular and genetic targets. Many risk factors for MPM development have been recognized including environmental exposures, genetic susceptibility, viral contamination, and radiation. However, the late stage of MPM diagnosis and the long latency that exists between some exposures and diagnosis have made it difficult to comprehensively evaluate the role of risk factors and their downstream molecular effects. In this review, we discuss the current molecular and genetic contributors in MPM pathogenesis and the risk factors associated with these carcinogenic processes.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,629
633
3
RESEARCH
Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells
Marjan J Van Erk, Eva Teuling, Yvonne CM Staal, Sylvie Huybers, Peter J Van Bladeren, Jac MMJG Aarts, Ben van Ommen
2004, 3:8 (12 May 2004)
DOI
:10.1186/1477-3163-3-8
PMID
:15140256
Background:
Curcumin is a spice and a coloring food compound with a promising role in colon cancer prevention. Curcumin protects against development of colon tumors in rats treated with a colon carcinogen, in colon cancer cells curcumin can inhibit cell proliferation and induce apoptosis, it is an anti-oxidant and it can act as an anti-inflammatory agent. The aim of this study was to elucidate mechanisms and effect of curcumin in colon cancer cells using gene expression profiling.
Methods:
Gene expression changes in response to curcumin exposure were studied in two human colon cancer cell lines, using cDNA microarrays with four thousand human genes. HT29 cells were exposed to two different concentrations of curcumin and gene expression changes were followed in time (3, 6, 12, 24 and 48 hours). Gene expression changes after short-term exposure (3 or 6 hours) to curcumin were also studied in a second cell type, Caco-2 cells.
Results:
Gene expression changes (>1.5-fold) were found at all time points. HT29 cells were more sensitive to curcumin than Caco-2 cells. Early response genes were involved in cell cycle, signal transduction, DNA repair, gene transcription, cell adhesion and xenobiotic metabolism. In HT29 cells curcumin modulated a number of cell cycle genes of which several have a role in transition through the G2/M phase. This corresponded to a cell cycle arrest in the G2/M phase as was observed by flow cytometry. Functional groups with a similar expression profile included genes involved in phase-II metabolism that were induced by curcumin after 12 and 24 hours. Expression of some cytochrome P450 genes was downregulated by curcumin in HT29 and Caco-2 cells. In addition, curcumin affected expression of metallothionein genes, tubulin genes, p53 and other genes involved in colon carcinogenesis.
Conclusions:
This study has extended knowledge on pathways or processes already reported to be affected by curcumin (cell cycle arrest, phase-II genes). Moreover, potential new leads to genes and pathways that could play a role in colon cancer prevention by curcumin were identified.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,388
860
37
ORIGINAL ARTICLE
High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium
Esraa A AL-Dujaily, Asad A Al-Janabi, Tomasz Pierscionek, Akeel A Yasseen
2008, 7:8 (10 November 2008)
DOI
:10.4103/1477-3163.44026
PMID
:19008567
Background:
This study aimed to estimate the rate of HER-2/neu (c-erbB2) immunohistochemical overexpression in different histological types of breast cancer found in the middle Euphrates region of Iraq, a region that was exposed to high levels of depleted uranium. HER-2/neu (c-erbB2) overexpression was correlated with common clinicopathological parameters such as age, grade, stage, tumor size and lymph node involvement to determine if any particular biomarker for exposure to depleted uranium could be found in the tumor samples from this region.
Materials and Methods:
The present investigation was performed over a period starting from September 2007 to June 2008. Formalin-fixed, paraffin-embedded blocks from 90 patients with breast cancer were included in this study. A group of 25 patients with benign breast lesions (fibroadenoma) was included as a comparative group, and 20 breast tissue sections were used as controls. Labeled streptavidin-biotin (LSAB) complex method was employed for immunohistochemical detection of HER-2/neu.
Results:
HER-2/neu immuno-expression was positive in 67.8% of breast cancer, while it was negative in all benign breast lesions (fibroadenoma) (
P
< 0.05). HER-2/neu immunostaining was significantly associated with histological type and recurrence of breast cancer (
P
< 0.05). It was positively correlated with tumor grade, but this finding was not significant (
P
> 0.05).
Conclusion:
Based upon the findings of this study, it can be concluded that HER-2/neu overexpression plays an important role in the pathogenesis of breast cancer and is associated with a worse prognosis. The findings indicate that in regions exposed to high levels of depleted uranium, HER-2/neu overexpression is high, but its correlation with age, grade, stage, tumor size, and lymph node involvement is similar to studies that have been conducted on populations not exposed to depleted uranium.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,520
663
6
MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer
Leonardo Faoro, Gustavo M Cervantes, Benjamin D Ferguson, Tanguy Y Seiwert, Soheil Yala, Wicki T Vigneswaran, Maria Westerhoff, Maria S Tretiakova, Mark K Ferguson, Glaci L Moura, Aliya N Husain, Everett E Vokes, Ravi Salgia
2009, 8:15 (24 November 2009)
DOI
:10.4103/1477-3163.57857
PMID
:19955662
Background:
Treatment of non-small cell lung cancer (NSCLC) remains a difficult task in oncology. Targeted inhibition of oncogenic proteins is promising. In this study, we evaluate the expression of MET and PKCß and in vitro effects of their inhibition using SU11274 and enzastaurin (LY317615.HCl) respectively.
Materials and Methods:
Patient samples were analyzed by immunohistochemistry for expression of PKCß and MET, utilizing tissue microarrays under an IRB-approved protocol. Expression of PKCß and MET was evaluated in cell lines by immunoblotting. Treatment with SU1174 against MET and enzastaurin against PKCß was performed in H1993 and H358 cell lines, and cell proliferation and downstream signaling (phosphorylation of MET, AKT, FAK, and GSK3ß) were evaluated by immunoblotting. Statistical analysis was performed using SPSS 16.0.
Results:
Expression of MET positively correlated with lymph node metastases (p=.0004), whereas PKCß showed no correlation (p=0.204). MET and PKCß expression were also strongly correlated (p<0.001). Expression of MET was observed in 5/8 cell lines (H358, H1703, A549, H1993, H2170; absent from H522, H661, or SW1573), whereas PKCß expression was observed in 8/8 cell lines. Cell proliferation was significantly impaired by treatment with SU11274 and enzastaurin, and their effects were synergistic in combination (CI=0.32 and 0.09). Phosphorylation of MET, FAK, AKT, and GSK3ß were strongly inhibited with both agents in combination.
Conclusions:
Concomitant inhibition of MET and PKCß significantly increased cytotoxicity in vitro against NSCLC, disrupting important downstream signaling pathways. Further evaluation in animal models is warranted.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,628
548
2
RESEARCH
Colon-available raspberry polyphenols exhibit anti-cancer effects on
in vitro
models of colon cancer
Emma M Coates, Gina Popa, Chris IR Gill, Mark J McCann, Gordon J McDougall, Derek Stewart, Ian Rowland
2007, 6:4 (18 April 2007)
DOI
:10.1186/1477-3163-6-4
PMID
:17442116
Background
There is a probable association between consumption of fruit and vegetables and reduced risk of cancer, particularly cancer of the digestive tract. This anti-cancer activity has been attributed in part to anti-oxidants present in these foods. Raspberries in particular are a rich source of the anti-oxidant compounds, such as polyphenols, anthocyanins and ellagitannins.
Methods
A "colon-available" raspberry extract (CARE) was prepared that contained phytochemicals surviving a digestion procedure that mimicked the physiochemical conditions of the upper gastrointestinal tract. The polyphenolic-rich extract was assessed for anti-cancer properties in a series of
in vitro
systems that model important stages of colon carcinogenesis, initiation, promotion and invasion.
Results
The phytochemical composition of CARE was monitored using liquid chromatography mass spectrometry. The colon-available raspberry extract was reduced in anthocyanins and ellagitannins compared to the original raspberry juice but enriched in other polyphenols and polyphenol breakdown products that were more stable to gastrointestinal digestion. Initiation - CARE caused significant protective effects against DNA damage induced by hydrogen peroxide in HT29 colon cancer cells measured using single cell microgelelectrophoresis. Promotion - CARE significantly decreased the population of HT29 cells in the G
1
phase of the cell cycle, effectively reducing the number of cells entering the cell cycle. However, CARE had no effect on epithelial integrity (barrier function) assessed by recording the trans-epithelial resistance (TER) of CACO-2 cell monolayers. Invasion - CARE caused significant inhibition of HT115 colon cancer cell invasion using the matrigel invasion assay.
Conclusion
The results indicate that raspberry phytochemicals likely to reach the colon are capable of inhibiting several important stages in colon carcinogenesis
in vitro
.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,397
773
22
ORIGINAL ARTICLE
The p53-induced Siva-1 plays a significant role in cisplatin-mediated apoptosis
John L Barkinge, Radhika Gudi, Hawkins Sarah, Fei Chu, Alip Borthakur, Bellur S Prabhakar, Kanteti V.S Prasad
2009, 8:2 (7 February 2009)
DOI
:10.4103/1477-3163.45389
PMID
:19240372
Background:
The pro-apoptotic protein Siva-1 functions in both extrinsic and intrinsic cell death signaling; however, the exact contribution of the endogenous Siva-1 to DNA damage-induced apoptosis is unclear. Using cisplatin, a chemotherapeutic drug, to induce DNA damage and cell death, we determined the role of Siva-1.
Methods:
Cisplatin treated HCT116 colorectal carcinoma cells (p53+/+ and -/-) were used in the study. With the help of recombinant lentivirus that can express siSiva (siRNA that specifically targets Siva-1), we also generated Siva-1 knockdown HCT116 cells. Apoptosis was determined by tetramethyl rhodamine methyl ester (TMRM) staining and propidium iodide (PI) staining.
Results:
Treatment with cisplatin induced Siva-1 expression in a p53 dependent manner. In Siva-1 knockdown p53+/+ HCT116 colorectal carcinoma cells, loss of Siva-1 expression conferred significant resistance to cisplatin-induced apoptosis. Although Siva-1 levels were positively regulated by p53, Siva-1-induced apoptosis did not require p53. Despite the fact that Siva-1 lacks even a minimal BH3 domain, similar to other proapoptotic Bcl2 family members induced by p53, we showed that Siva-1 mediated apoptosis is characterized by Bax oligomerization and cytochrome c leakage from mitochondria. The putative amphipathic helical region in Siva-1 (SAH) appeared to function analogously to a BH3 domain.
Conclusion:
The p53 induced Siva-1 is one of the effector molecules, which plays a significant role in DNA damage-induced cell death.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,400
638
5
RESEARCH
The role of c-kit and imatinib mesylate in uveal melanoma
Patricia Rusa Pereira, Alexandre Nakao Odashiro, Jean Claude Marshall, Zelia Maria Correa, Rubens Belfort Jr, Miguel N Burnier Jr
2005, 4:19 (19 October 2005)
DOI
:10.1186/1477-3163-4-19
PMID
:16236162
Background:
Uveal melanoma (UM) is the most common primary intraocular tumor in adults, leading to metastasis in 40% of the cases and ultimately to death in 10 years, despite local and/or systemic treatment. The c-kit protein (CD117) is a membrane-bound tyrosine kinase receptor and its overexpression has been observed in several neoplasms. Imatinib mesylate is a FDA approved compound that inhibits tyrosine quinase receptors, as well as c-kit. Imatinib mesylate controls tumor growth in up to 85% of advanced gastrointestinal stromal tumors, a neoplasia resistant to conventional therapy.
Methods:
Fifty-five specimens of primary UM selected from the archives of the Ocular Pathology Laboratory, McGill University, Montreal, Canada, were immunostained for c-kit. All cells displaying distinct immunoreactivity were considered positive. Four human UM cell lines and 1 human uveal transformed melanocyte cell line were tested for i
n vitro
proliferation Assays (TOX-6) and invasion assay with imatinib mesylate (concentration of 10 μM).
Results:
The c-kit expression was positive in 78.2% of the UM. There was a statistical significant decrease in the proliferation and invasion rates of all 5 cell lines.
Conclusion:
The majority of UM expressed c-kit, and imatinib mesylate does decrease the proliferation and invasion rates of human UM cell lines. These results justify the need for a clinical trial to investigate in vivo the response of UM to imatinib mesylate.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,535
464
16
REVIEW
Estrogen, mitochondria, and growth of cancer and non-cancer cells
Quentin Felty, Deodutta Roy
2005, 4:1 (15 January 2005)
DOI
:10.1186/1477-3163-4-1
PMID
:15651993
In this review, we discuss estrogen actions on mitochondrial function and the possible implications on cell growth. Mitochondria are important targets of estrogen action. Therefore, an in-depth analysis of interaction between estrogen and mitochondria; and mitochondrial signaling to nucleus are pertinent to the development of new therapy strategies for the treatment of estrogen-dependent diseases related to mitochondrial disorders, including cancer.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,296
662
35
ORIGINAL ARTICLE
Gli1 maintains cell survival by up-regulating IGFBP6 and Bcl-2 through promoter regions in parallel manner in pancreatic cancer cells
Xuan-Fu Xu, Chuan-Yong Guo, Jun Liu, Wen-Juan Yang, Yu-Jing Xia, Ling Xu, Yong-Chun Yu, Xing-Peng Wang
2009, 8:13 (3 September 2009)
DOI
:10.4103/1477-3163.55429
PMID
:19736394
Background:
Aberrant activation of Hedgehog (Hh) signaling pathway has been reported to be related to malignant biological behavior of pancreatic cancer but its mechanism is unclear yet. Since IGF pathway and Bcl-2 family are involved in proliferation and apoptosis of pancreatic cancer cells, we hypothesize that they are possibly associated with Hh pathway.
Materials and Methods:
We studied the relationship of Shh-Gli1 signaling pathway with proliferation and apoptosis of pancreatic cancer cells and the regulation of transcription factor Gli1 to insulin-like growth factor binding protein 6 (IGFBP6) and Bcl-2 genes at the level of transcription.
Results:
Sonic hedgehog (Shh), Smoothened (Smo), patched and Gli1 were expressed in pancreatic cancer cells. Cyclopamine inhibited cell proliferation at low concentration and induced apoptosis at high concentration. Effect of RNA interference (RNAi) for Gli1 to cell survival is mainly due to proliferation inhibition though involved in apoptosis. The transcription factor Gli1 bound to promoter regions of Bcl-2 and IGFBP6 genes and the levels of IGFBP6, proliferating cell nuclear antigen (PCNA) and Bcl-2 messenger RNA (mRNA) were decreased as well as Gli1 mRNA significantly by cyclopamine or RNAi in cultured pancreatic cancer cells (p < 0.01). Finally PCNA, IGFBP6 and Bcl-2 mRNA were upregulated as well as Shh or Gli1 in pancreatic cancer tissues (p < 0.01).
Conclusions:
Our study reveals that Gli1 maintained cell survival by binding the promoter regions and facilitating transcription of IGFBP6 and Bcl-2 genes in a parallel manner in pancreatic cancer cells and suggests it may be one of the mechanisms of Shh-Gli1 signaling pathway in pancreatic cancer.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,116
832
4
Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer
Jose Pontes-Junior, Sabrina Thalita Reis, Marcos Dall'Oglio, Luis Carlos Neves de Oliveira, Jose Cury, Paulo Afonso Carvalho, Leopoldo Alves Ribeiro-Filho, Katia Ramos Moreira Leite, Miguel Srougi
2009, 8:3 (25 February 2009)
DOI
:10.4103/1477-3163.48453
PMID
:19240373
Background:
Integrins and adhesion molecules are responsible for the maintenance of the epithelial phenotype. Cell culture studies have reported the correlation between adhesion molecule expression and prostate carcinoma, but their role in the metastatic process is not yet known. Our aim is to study the expression profiles of these molecules and evaluate their association with the metastatic behavior of prostate adenocarcinoma.
Materials and Methods:
A Tissue Microarray containing two samples from 19 primary tumors and one from their corresponding lymph node metastases was constructed and subjected to immunohistochemical analysis of the expression of integrins, E-cadherin and β and γ-catenins. Within each case, paired analyses were also performed to evaluate gains or losses in metastasis compared to its primary tumor.
Results:
The expression of av, αvβ 3, α2β 1 and γ-catenin were abnormal in almost every case. Marked loss of E-cadherin and β 4 integrin was found in primary and metastatic lesions. β -catenin was normal in all primary cases and in 94% of metastases. a6 was normal in all primary tumors and metastases. α3 and α3β 1 were normal in 32% of primary cases and in 53% and 6% of metastases, respectively. In paired analyses, loss of E-cadherin, β 4, αv, α3β 1 and αvβ 3 was found in 65%, 71%, 59%, 53% and 47% of patients, respectively. Catenins and α2β 1 showed maintenance of expression in most of the cases.
Conclusions:
In this preliminary study we have shown that the loss of cell adhesion molecules can be considered a characteristic of the metastatic phenotype in prostate cancer. Larger series should be evaluated in order to confirm our findings.
[ABSTRACT]
[FULL TEXT]
[PDF]
[CITATIONS]
[PubMed]
3,112
785
9
REVIEW ARTICLE
Paget's disease of the breast
Cansu Karakas
2011, 10:31 (8 December 2011)
DOI
:10.4103/1477-3163.90676
PMID
:22279416
Paget's disease of the breast is a rare type of cancer of the nipple-areola complex and that is often associated with an underlying
in situ
or invasive carcinoma. This article provides an overview and we review the main clinicopathological and therapeutic features of mammary Paget's disease.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
3,531
170
-
Feedback
Search
Submit article
Instructions
Subscribe
Advertise
Contact Us
A peer reviewed journal in the field of Carcinogenesis and Chemoprevention For the Researchers - By the Researchers - Of the Researchers
Sitemap
|
What's New
|
Feedback
|
Disclaimer
© Journal of Carcinogenesis | Published for Carcinogenesis Press by
Medknow Publications
Online since 25 June, 2011